-
公开(公告)号：US20240299521A1
公开(公告)日：2024-09-12
申请号：US18664120
申请日：2024-05-14
申请人： NantBio, Inc.
发明人： Kayvan Niazi , Raymond Wong , Peter Sieling , Philip T. Liu
IPC分类号： A61K39/108 , A61K9/00 , A61K39/00 , C12N15/861
CPC分类号： A61K39/0258 , A61K39/0002 , C12N15/861 , A61K9/0019 , A61K2039/605 , C12N2770/16034
摘要： Two-component vaccine formulations and methods are contemplated where the vaccine has an adjuvant component and a therapeutic component. The therapeutic component comprises preferably a recombinant therapeutic virus encoding a therapeutic antigen while the adjuvant component comprises a non-host cell or immune stimulating portion thereof. Notably, use of the adjuvant component will result in significant uptake of the therapeutic component into immune competent cells, even in the absence of receptors for entry of the therapeutic component. In addition, such adjuvant also stimulates expression of the therapeutic antigen.
-
公开(公告)号：US12016883B2
公开(公告)日：2024-06-25
申请号：US17033265
申请日：2020-09-25
申请人： NantBio, Inc.
发明人： Krsto Sbutega , Peter Sieling , Adam D. Lazar , Kayvan Niazi
IPC分类号： A61K35/17 , A61K45/00 , C07K16/28 , C12N5/0783
CPC分类号： A61K35/17 , A61K45/05 , C07K16/2806 , C07K16/2809 , C07K16/2818 , C12N5/0636 , C12N2501/20
摘要： Provided herein are methods of in-vitro primary T cell growth that enrich T cells in a blood sample, stimulate the T cells with anti-CD2, anti-CD3, and/or anti-CD28 and that expand the T cells with a cytokine. Also provided are methods of treating a tumor in a patient using the expanded T cells.
-
公开(公告)号：US20240197786A1
公开(公告)日：2024-06-20
申请号：US18415101
申请日：2024-01-17
申请人： NantBio, Inc.
摘要： Compositions and methods are presented that include exosomes from stem cells and/or tumor cells that were previously exposed to an inflammatory stimulus. Advantageously, such exosomes exhibit anti-inflammatory and analgesic effect when administered to an individual. Therefore, a preferred use of such exosomes will reduce the need for opioid analgesics, and reduce pain and inflammation.
-
公开(公告)号：US20240084011A1
公开(公告)日：2024-03-14
申请号：US18001566
申请日：2021-06-09
申请人： NantBio, Inc.
发明人： Clifford Anders Olson , Shiho Tanaka , Kayvan Niazi , Melanie Hermreck , Thomas H. King , Zhimin Guo
CPC分类号： C07K16/2818 , A61K49/0002 , A61P35/00 , C07K2317/35 , C07K2317/622
摘要： Compositions and methods are presented in which selected polypeptide compounds bind to CTLA-4. Most typically, binding is mediated by selected VH and/or VL domains, and preferred compounds are prepared as scFv, IgG, or CAR.
-
公开(公告)号：US20240018274A1
公开(公告)日：2024-01-18
申请号：US18339155
申请日：2023-06-21
申请人： NantBio, Inc.
发明人： Kayvan Niazi , Wael Tadros , Annie Shin
IPC分类号： C07K19/00 , C07K14/575 , C07K14/725 , C12N15/10 , C12N15/86
CPC分类号： C07K19/00 , C07K14/575 , C07K14/7051 , C12N15/102 , C12N15/86 , C07K2319/912 , C12N2710/10111
摘要： Compositions and methods are presented that allow for an enhanced immune response against a GPI-anchored tumor associated antigen by modification of the protein portion of the TAA to include a transmembrane domain and a trafficking signal that directs the modified protein to the endosomal or lysosomal compartment. Most preferably, the modified protein will no longer have a GPI anchor or GPI attachment sequence.
-
公开(公告)号：US11034951B2
公开(公告)日：2021-06-15
申请号：US16264304
申请日：2019-01-31
申请人： NantBio, Inc.
摘要： Compositions, methods and uses of a recombinant virus and/or recombinant viral vector encoding a distinct antibody or antibody fragment generated from high-diversity nucleic acid library are presented. Preferably, the recombinant virus is genetically modified, low immunogenic virus, for example, an E2b-deleted adenovirus. The high-diversity nucleic acid library comprises or is derived from (1) a VH-CDR1/2 sub-library, (2) a plurality of VH-CDR3 sub-libraries, and (3) a VL sub-library, each of which comprises a plurality of members. Preferably, each member of the sub-libraries comprises at least one random cassette that has a plurality of degenerate base positions. In an especially preferred embodiment, at least portions of at least two members of the VH-CDR1/2 sub-library, the plurality of VH-CDR3 sub-libraries, and the VL sub-library are recombined to form an expression library member in an expression library, where each member of the expression library encodes a distinct antibody or antibody fragment.
-
公开(公告)号：US20210061871A1
公开(公告)日：2021-03-04
申请号：US17006184
申请日：2020-08-28
申请人： NantBio, Inc.
发明人： Kayvan Niazi , Heather McFarlane
IPC分类号： C07K14/54 , C07K14/495 , C12N15/63 , C07K16/28
摘要： Compositions and methods for multi-specific protein complexes comprising an interleukin-15 (IL-15) domain comprising an N72D mutation (IL-15N72D), a IL-15 receptor alpha sushi-binding domain (IL-15RαSu), an immunoglobulin Fc domain, and a mutated transforming growth factor-beta receptor type 2 (TGFβRII) domain, wherein the mutated TGFβRII domain has a N->Q mutation in positions 47, 71, and 131 respectively. The IL-15RαSu domain, the Fc domain, and the mutated TGFβRII domain are sequentially linked by amide bonds. Preferably, contemplated complexes further include a binding domain that specifically binds to a disease antigen, immune checkpoint molecule, or immune signaling molecule.
-
公开(公告)号：US20200024326A1
公开(公告)日：2020-01-23
申请号：US16440790
申请日：2019-06-13
申请人： NANTBIO, INC.
发明人： Kayvan Niazi , Gard Nelson , Wendy Higashide , Philip Liu
IPC分类号： C07K14/705 , C12N15/85 , A61K35/15
摘要： Self-activating chimeric signaling proteins, and especially chimeric TNF family member ligand-receptor proteins are contemplated. In preferred methods, the chimeric protein comprises an extracellular portion of CD40L that is coupled via a flexible linker to CD40 such that the fusion protein, when expressed in an APC, is capable of folding back on itself and transmits a CD40-mediated signal as if it had been contacted by CD40L located on another cell. Advantageously, cells expressing such chimeric proteins contemporaneously with presentation of an antigen will enhance an immune reaction against the antigen.
-
公开(公告)号：US20240360191A1
公开(公告)日：2024-10-31
申请号：US18769216
申请日：2024-07-10
申请人： NantBio, Inc.
IPC分类号： C07K14/54 , A61K35/17 , C12N5/0783
CPC分类号： C07K14/5434 , A61K35/17 , C12N5/0646 , C07K2317/24 , C07K2317/55 , C07K2317/622 , C07K2319/01 , C07K2319/33
摘要： Compositions and methods for NK cell based treatments, and particularly NK cells that express and intracellularly retain IL-2, are presented in which the NK cells are stimulated with a chimeric protein that has a cancer cell targeting portion and an IL-12 portion. Beneficially, such chimeric protein has substantially reduced systemic toxicity and induces IFN-γ secretion in a targeted manner. Moreover, chimeric proteins contemplated herein also significantly enhanced IFN-γ secretion in NK cells that express and intracellularly retain IL-2 as compared to native NK cells. Preferred chimeric proteins comprise SEQ ID NO:1 or SEQ ID NO:2, and SEQ ID NO:3.
-
10.发明公开公开(公告)号：US20240350603A1
公开(公告)日：2024-10-24
申请号：US18761799
申请日：2024-07-02
IPC分类号： A61K39/00 , G01N33/50 , G01N33/569
CPC分类号： A61K39/0011 , G01N33/505 , G01N33/5052 , G01N33/56977 , A61K2039/5158 , A61K2039/605 , A61K2039/6081
摘要： The invention provides a method of validating the therapeutic composition that is prepared for immunotherapy of a tumor or cancer. The method includes, triggering of an immune response to a neoepitope of a subject's tumor by:
a) obtaining neoepitope sequence data from the tumor of a subject;
b) obtaining immune competent cells;
c) using the neoepitope sequence data to generate a neoepitope presentation system;
d) triggering an immune response by contacting the immune competent cells with the neoepitope presentation system; and
e) quantifying the triggering of the immune response from the contacted immune competent cells.
-
-
-
-
-
-
-
-
-
搜索结果
63 条记录 (耗时 0.022 秒)
